# Junta clínica — PT-pseudo_b9aa0df93f2a (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9aa0df93f2a",
  "pid": "PT-pseudo_b9aa0df93f2a",
  "task": 1,
  "psa": 5.5,
  "age": 71,
  "months": 1,
  "pirads": "5",
  "psad": 0.12,
  "psav": 1.47,
  "psap": 3.8,
  "vol": 49.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8111057,
  "medhx": "Hypertension",
  "meds": "amlodipine, lisinopril, metoprolol",
  "notes": "PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "116 kg",
    "height": "175 cm",
    "bmi": "37.9",
    "bp": "149/83 mmHg",
    "hr": "65 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "04 Feb 2025",
  "enc_ref": "Dr. F. de Boer (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result."
    },
    {
      "s": "History",
      "t": "A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent."
    },
    {
      "s": "Physical examination",
      "t": "Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent."
    }
  ],
  "occupation": "warehouse manager",
  "marital": "Married",
  "living": "Lives alone",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test"
  ],
  "alcohol": "2 units / week",
  "exercise": "Cycling 3x/week, ~30 km",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient anxious about procedures — allocate extra consult time.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9aa0df93f2a
Task: 1

Encounter: Urology - outpatient on 04 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 5.5 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 49.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8111057 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: amlodipine, lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 5.5 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 49 mL. csPCa 0.81.

Vitals: weight 116 kg, height 175 cm, BMI 37.9, BP 149/83 mmHg, HR 65 bpm. Smoking: Non-smoker.

Chief complaint: Assessment of a 5.5 ng/mL prostate-specific antigen elevation alongside a prior positive biopsy result.

History: A married, 71-year-old warehouse manager who lives alone with his spouse listed as the primary contact. Initial workup began in late 2023 after an elevated prostate-specific antigen was detected. He experiences moderate lower urinary tract symptoms, scoring 15 on the IPSS, mainly due to nocturia and a diminished urinary stream, while explicitly denying haematuria or pelvic discomfort. His medical background includes well-managed hypertension treated with amlodipine, lisinopril, and metoprolol, plus an arthroscopic knee procedure in his forties. He stays physically active by cycling roughly 30 kilometres three times weekly, drinks about two units of alcohol each week, and reports no tobacco use. A recent audiology visit identified mild age-related presbycusis, currently managed with hearing aids. He has voiced significant apprehension about invasive interventions and insists on detailed explanations of every potential step prior to providing consent.

Physical examination: Normal DRE: The prostate is symmetrically enlarged, smooth, and firm, with no palpable nodules or asymmetries. General inspection is unremarkable. Blood pressure measures 149/83 mmHg with a regular heart rate of 65 beats per minute. Abdominal palpation shows no suprapubic tenderness or distended bladder. Peripheral lymphadenopathy and bone tenderness are absent.

Patient info: warehouse manager; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 2 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.55
  uncertainty  +/- 0.16 epistemic (95% band 0.25-0.86); among patients I cannot tell apart the outcome was 0.99 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 1 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 71 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 5.5 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 49 mL (1% of my signal; from log_vol, vol) · PSA density = 0.12 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.81 (1% of my signal; from cspca) · PI-RADS = 5 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 71 · DRE = Normal · PSA = 5.5 ng/mL · prostate volume = 49 mL · PSA density = 0.12 · PI-RADS = 5 · comorbidity = 1 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.12: PI-RADS 5, PSA 11.0, PSAD 0.108, age 70, DRE Normal -> BIOPSY (borderline). He wrote: "Patient on Activ Surveillance with severe LUTS symptoms. There are two options , recommend surgery direkt or do a new biopsy."
  2. distance 1.26: PI-RADS 5, PSA 10.0, PSAD 0.27, age 75, DRE Normal -> BIOPSY (clear). He wrote: "New(? -> no old MRI report included) PIRADS 5 and rising PSA makes biopsy necessary"
  3. distance 1.61: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  decisive   PI-RADS = 5
  important  prior biopsy = Positive · age = 71 · PSA = 5.5 ng/mL
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 49 mL · PSA density = 0.12 · comorbidity = 1 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 71 · PSA = 5.5 ng/mL · PI-RADS = 5
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 49 mL · PSA density = 0.12 · comorbidity = 1 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The retrieved guideline discusses using a risk-adapted pathway based on PI-RADS score, PSA density, and prior biopsy status. It states, "In this pathway, biopsy could have been avoided in 99 men (19%) while missing ISUP GG 2 cancers in only six men (1.2%) [473]." This suggests that a risk-based pathway can guide the decision to avoid biopsy based on specific criteria.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your bid of BIOPSY p(biopsy) = 0.55 is not settled by the guideline, as the guideline suggests a risk-based pathway can avoid biopsy in 99 men if specific low-risk criteria are met. The guideline suggests that the prior biopsy status is a key factor that must be documented in the notes to determine the next step. The guideline requires the documented prior grade of the prior biopsy to settle the decision. The guideline needs the documented prior grade of the prior biopsy to make a decision.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the PSA velocity is a factor that the guideline uses in risk stratification.
laboratory_results - the PSA density: the PSA density is a factor that the guideline uses in risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges entirely on the documented grade of the prior biopsy and the PSA velocity, as the EAU guideline suggests a risk-adapted pathway based on these factors.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
  psa_trend (get_psa_trend) -> Does the PSA velocity inform the risk stratification?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> Does the PSA density inform the risk stratification?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade of the prior biopsy?
  Q2. What is the PSA velocity?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: mpMRI Prostate | Institution: LUMC, Leiden | Date: 28 January 2025
Does the lesion size and zone, extraprostatic extension, and comparison against an earlier study inform the decision?
The lesion is approximately 12 mm in size in the left peripheral zone, and there is no extraprostatic extension or seminal vesicle invasion. It is compared against an earlier study implicitly by being part of the current assessment.

psa_trend
Does the PSA velocity inform the risk stratification?
The PSA velocity shows a rise from 1.5 ng/mL/yr in Aug 2023 to 5.5 ng/mL in Feb 2025.

previous_notes
What is the documented grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
The documented grade of the prior biopsy is not explicitly stated in the retrieved notes. There was one prior consultation note on 10 Feb 2024 regarding the rising PSA and prior positive biopsy.

laboratory_results
Does the PSA density inform the risk stratification?
The PSA density is 0.12 ng/mL/mL.

WHAT I DID NOT OPEN
family-history anamnesis because the prior notes did not contain information on the documented grade of the prior biopsy, which is critical for the EAU guideline.

WHAT THIS SUPPORTS
FOR sampling this patient now
The PI-RADS 5 finding from the mpMRI suggests a high-risk lesion.
The rising PSA velocity supports the need for further investigation.

AGAINST sampling this patient now
The documented grade of the prior biopsy is not explicitly stated in the retrieved notes.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: INDETERMINATE (uncertain). Last value 5.50 ng/mL over 3 points spanning 18 months; velocity +2.67 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 6.5 ng/mL, conformal 95% band 1.9-22.5.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 5.5 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: uncertain — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.68
  uncertainty  +/- 0.16 epistemic (95% band 0.36-1.00), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 5 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 5.5 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 49 mL (4% of my signal; from log_vol, vol) · PSA density = 0.12 (0% of my signal; from psad_calc) · comorbidity = 1 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: borderline — 'supports' tier; out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.55  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.68  ('supports' tier, fusion_full; weight 3.0)
  EXPERT-EXPERIENCE  BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.65 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          71                           E1:not E3:— cohort:not library:IMP E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          5.5 ng/mL                    E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          49 mL                        E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.12                         E1:not E3:not cohort:not library:not E2:—            -> noted
  cspca        0.81                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       5                            E1:not E3:IMP cohort:not library:DEC E2:—            -> important
  comorbidity  1 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: clear.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) address the moderator's questions to some extent. The `psa_trend` answers Q2 by showing the PSA velocity (rise from 1.5 to 5.5 ng/mL in 18 months). However, the `previous_notes` explicitly state that the documented grade of the prior biopsy is "not explicitly stated."

ALIGNMENT WITH THE PANEL
The retrieved evidence does not align with the PANEL-PROTOCOL's conclusion that the decision rests on the documented prior grade, as the notes explicitly state this grade is missing. The finding that does the work against the panel's reliance on the notes is the registrar's report stating, "The documented grade of the prior biopsy is not explicitly stated in the retrieved notes."

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade of the prior biopsy? Answered by the registrar: "The documented grade of the prior biopsy is not explicitly stated in the retrieved notes." Q2. What is the PSA velocity? Answered by the registrar: "The PSA velocity shows a rise from 1.5 ng/mL/yr in Aug 2023 to 5.5 ng/mL in Feb 2025."

WHAT CARRIES WEIGHT, AND WHY
<prior biopsy>: not_used / noted with value: Positive, because the panel protocol explicitly states the decision hinges on this, and the notes failed to provide the necessary detail. I would move this to decisive because the lack of documentation is a critical missing piece for the guideline application.
<psa velocity>: important / noted with value: Rise from 1.5 ng/mL/yr to 5.5 ng/mL in 18 months, because the EAU guideline explicitly uses PSA velocity for risk stratification. I agree with the 'important' level as it is a key factor.
My confidence in the record as it stands is borderline because the critical piece of information required by the guideline (prior biopsy grade) is explicitly missing from the retrieved notes.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the documented grade of the prior biopsy is obtained, as the EAU guideline requires this information to determine the risk-adapted pathway.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

71y male, PSA 5.5, PI-RADS 5, prior positive biopsy with undocumented grade. The lack of prior ISUP grade mandates sampling to determine management pathway. While high PSA and PI-RADS 5 suggest treatment, the undocumented prior grade makes biopsy necessary to define the extent of disease.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
